Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...

Prevent Blindness has declared the first week of December as its 5th annual geographic atrophy (GA) week to educate the ...

Lid margin collarettes are common in moderate-to-severe DED, but most do not progress over time. No link was found between collarettes and dry eye symptoms. DED signs were more severe in eyes with ...

The CEO of Dean McGee Eye Institute reflects on the program’s milestones, global partnerships, and the future of ...

One of the most futuristic components of Hipsley’s work is the Virtual Eye Simulation Analyzer (VESA), an AI-enabled modeling ...

Aesthetic technologies are expanding ophthalmic practice into a broader sphere of patient care. AAO 2025 emphasized that ...

Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving ...

Panelists share how they tailor therapy based on patient characteristics, symptoms, and clinical findings.

AAVantgarde and AGC Biologics have entered into an agreement in which AGC Biologics will provide Good Manufacturing Practice manufacturing for AAVantgarde’s dual-vector gene therapies for inherited ...